Oncgnostics
Cancer Diagnostics Detecting Epigenetic Biomarkers
Blood glucose monitoring solutions provider LifeScan has launched a new version of its diabetes management mobile app OneTouch Reveal which now has new features.
Blood glucose monitoring solutions provider LifeScan has launched a new version of its diabetes management mobile app OneTouch Reveal which now has new features.
OneTouch Reveal is designed to enable the wireless monitoring of blood sugar. Users will also be able to share the results with their healthcare team.
The new version comes with functionality to automatically identify recurring highs or lows in the blood sugar and alerts users on their smartphones.
In addition, the new OneTouch Reveal allows patients to set and track their personalised goals for blood glucose tests, carbohydrates logging and other daily activities.
They can also use the diabetes management tool to compare their 90-day average to the logged lab A1c in order to check the levels of their blood sugar over time.
The app is currently available for use in a total of 24 countries, including Belgium, Canada, France, Germany, India, the US, Italy, Ireland, Spain, the UAE, Poland and the UK.
Last month, LifeScan secured the European CE-Mark for the OneTouch Verio Reflect system with Blood Sugar Mentor. The company is planning for the commercial launch of the device in France this month, with an introduction to additional EMEA markets planned for next year.
Furthermore, LifeScan is seeking approvals for the OneTouch Verio Reflect system in the US and Canada.
The company said that the device can be synced with the OneTouch Reveal app for additional features such as Blood Sugar Mentor alerts and customisation of system settings from the app.
GlobalData's TMT Themes 2021 Report tells you everything you need to know about disruptive tech themes and which companies are best placed to help you digitally transform your business.
Find out moreLifeScan was a division of Johnson and Johnson, which recently divested the company to private investment firm Platinum Equity for approximately $2.1bn.
Cancer Diagnostics Detecting Epigenetic Biomarkers
Custom-Designed CMOS Image Sensor Solutions and Instrument and Camera Integrators
Medical Device Manufacturing and Quality Control